Flu Trends May Shape Future Earnings For Drug Makers
Rising flu-like illness could impact 2027 growth projections for health manufacturers Reckitt and Haleon.
Updated on Oct. 21, 2026 in Stock Picks

Live Poll
Do you trust that consumer health companies provide reliable long-term growth outlooks to their shareholders?
UBS analysts suggest that upcoming flu season trends could influence future earnings for Reckitt and Haleon through 2027. Rising flu-like illnesses in the United States, United Kingdom, and Germany indicate a potential shift in the performance of respiratory medicine segments for these companies.
Why it matters
Flu seasons over the last two and a half years have been weaker than average, which historically hindered sales growth for these major health manufacturers. Because respiratory products contribute significant portions of their operating profits, analysts are closely monitoring current incidence rates to project future revenue stability.
For the week ending October 4, 2026, flu-like illness accounted for 2.1% of US doctor visits, an increase from 1.6% in the same period last year. US sales of upper respiratory medicines rose 3.4% in the four weeks leading up to October 3, 2026.
The players
UBS
An international investment bank that provides market analysis and earnings forecasts for publicly traded companies.
Reckitt
A consumer goods company that produces health and hygiene products, including various over-the-counter respiratory medications.
Haleon
A global consumer healthcare company focused on manufacturing over-the-counter medicines, vitamins, and oral health products.
The details
UBS calculates these growth projections by comparing historical sales data against periods of weaker seasonal flu activity. Reckitt currently derives 12% of its core sales from cough, cold, and flu products, while Haleon draws 11% of its revenue from the same category. If flu incidence matches 2023-24 levels, analysts anticipate Reckitt could see 5.2% like-for-like sales growth by 2027, though Haleon may be forced to revise its growth targets downward if the season proves milder than expected.
Timeline
Week to October 3, 2026: US upper respiratory medicine sales rose 3.4%.
Week to October 4, 2026: Flu-like illness accounted for 2.1% of US doctor visits.
2027: Projected earnings period for Reckitt and Haleon.
Money Landscape
Investment valuations for major healthcare manufacturers are increasingly sensitive to seasonal health patterns that impact retail medicine demand. This analysis aligns with broader trends where analysts adjust long-term growth forecasts to account for the impact of multi-year periods of lower-than-average seasonal illness.
Investors monitoring these companies should note that potential earnings volatility is tied to the severity of the current flu season. Fluctuations in seasonal product demand often serve as a bellwether for the broader performance of consumer healthcare stock portfolios.
The takeaway
The projected earnings for these major healthcare firms are closely linked to seasonal health trends that affect consumer demand for respiratory products. Monitoring public health data regarding respiratory illness can provide useful context for understanding the potential growth trajectories of these companies.
Further reading
For more information on how seasonal market trends influence consumer health companies, visit our Stock Picks section.
Source note: This article includes information reported by Proactiveinvestors NA.
Live Poll
Do you trust that consumer health companies provide reliable long-term growth outlooks to their shareholders?


